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Abstract 
 
         Qidantongmai (QDTM) is a Traditional Chinese Medicine (TCM) preparation that has long been used in folk 
medicine for the treatment of cardiovascular diseases. However, the underlying mechanisms are poorly understood. The 
present study was designed to determine the effects of QDTM on endothelial cells under hypoxic conditions both in vitro and 
in vivo. Primary human umbilical vein endothelial cells (HUVECs) were isolated, pretreated with QDTM medicated serum 
or saline control, and then cultured under hypoxia (2% oxygen) for 24 h. Sprague-Dawley rats were administered 1 ml/100 g 
of QDTM or saline twice a day for 4 days and treated with hypoxia (6 hours/day, discontinuous hypoxia, 360 mm Hg). 
QDTM not only protected HUVECs from hypoxia-induced damage by significantly retaining cell viability (P < 0.05) and 
decreasing apoptosis (P < 0.05) in vitro, but also protected liver endothelial cells from hypoxia-induced damage in vivo. 
Moreover, QDTM increased the serum VEGF-A level (P < 0.05) in rats treated with hypoxia for 7 days but suppressed the 
upregulation of serum VEGF-A in rats treated with hypoxia for 14 days. QDTM is a potent preparation that can protect 
endothelial cells against hypoxia-induced damage. The ability of QDTM to modulate the serum VEGF-A level may play an 
important role in its effects on endothelial cells.  
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Introduction 
 
         Natural herbal products have been used in Traditional Chinese Medicine (TCM) for centuries, and increasing 
evidence supports the effectiveness of TCM in clinical therapies and animal experiments. For example, Qidantongmai 
(QDTM), a TCM formulation that has been used to treat brain ischemia-reperfusion damage, myocardial 
ischemia-reperfusion damage, atherosclerosis, thrombosis, and coronary artery diseases (Ma et al., 2000; Wang et al., 1998; 
Zhang et al., 2001a), is composed of Astragalus, Salvia, Angelica sinensis, Ramulus cinnamoni, and Carthamus tinctorius. 
All five of these TCMs are widely used to treat cardiovascular diseases, such as angina pectoris, myocardial infarction, and 
atherosclerosis. The present study was designed to determine the effects of QDTM on human endothelial cells and to 
uncover the underlying mechanisms for its actions.  
         Ischemia, which is characterized by decreased oxygen delivery and nutrient supply to tissues, is involved in many 
human diseases, such as thrombosis, atherosclerosis, myocardial infarction, and cerebral ischemia (Kanagy, 2009; Morgan, 
2007). Endothelial cells are the first target in ischemia-induced hypoxia (Paternotte et al., 2008; Ten and Pinsky, 2002), 
resulting in the activation of endothelial cells (Paternotte et al., 2008). Thus, it is important to develop strategies for 
prevention and treatment of hypoxia-induced cellular and tissue damage. Although QDTM has been used to treat 
cardiovascular disorders for many years, the effects and mechanisms of QDTM on endothelial cells under hypoxic 
conditions have not been investigated.  
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Vascular endothelial growth factor (VEGF) is a major regulator of endothelial proliferation and migration (Majesky, 1996). 
The seven members of the VEGF family are VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, VEGF-F, and PIGF. As a key 
target for new anti-angiogenic drugs for the treatment of both malignant and nonmalignant human diseases, VEGF exhibits 
multiple functions (Ellis and Hicklin, 2008). Moreover, VEGF-modulated vascular biological functions may contribute to the 
development and progression of several human diseases, including cardiovascular diseases, cancer, and diabetic 
complications. Therefore, targeting VEGF is a potentially effective approach for the treatment of ischemic disorders. 
Upregulation of VEGF has been observed in tumors and under various conditions such as hypoxia and wound healing (Fan 
et al., 2002; Mori et al., 2009). In the present study, the serum levels of VEGF-A, which is generally considered to be a blood 
vessel-specific angiogenesis factor, was measured to explore the mechanism underlying the protective effects of QDTM on 
endothelial cells. 
 
 
Materials and Methods 
Animals  
 
         Male Sprague-Dawley (SD) rats weighing 250 ± 20 g were purchased from the Experimental Center of The 
Fourth Military Medical University, Xi’an, China, and  housed under controlled conditions (temperature 23oC ± 1oC, 
humidity 60% ± 10%, 12-h/12-h light/dark rhythm) and with free access to water and chow. The animal experiments were 
approved by the Ethics Committee for Animal Use of The Fourth Military Medical University. 
 
QTCM and medicated serum preparation  
 
         The QDTM tablets were kindly provided by Xijing Hospital (Xi’an, China). To prepare the QDTM medicated 
serum preparation, SD rats were given QDTM orally at a dose of 3.24 g/kg twice a day for 4 days. Blood samples were taken 
1 h after the last dosing and centrifuged to prepare medicated serum. Serum was frozen at –80 oC until use. The control 
serum was collected from normal rats treated with saline. 
 
Cells and cell culture  
 
         Human umbilical vein endothelial cells (HUVECs) were isolated from fresh human umbilical veins as described 
previously, with some modifications (Fan et al., 2002). The study was reviewed and approved by the Ethics Review Board of 
the Fourth Military Medical University, and all participants gave informed consent. Briefly, to prepare HUVECs, human 
umbilical veins were harvested from umbilical cords under sterile conditions, flushed with phosphate-buffered saline (PBS), 
filled with PBS containing 0.2% collagen II (from Sigma-Aldrich Company, St. Louis, MO) , and then incubated for 20 mins 
at 37 °C. The HUVECs were then collected and washed with PBS. The isolated primary HUVECs were maintained in 2% 
gelatin-coated tissue culture plates in complete growth medium 199 supplemented with 20% fetal bovine serum, 10 µg/ml of 
endothelial cell growth factor (from Gibco BRL, Life Technologies，New York, USA), 10 mg/ml of heparin, and 
penicillin-streptomycin (50 mg/ml each) at 37 oC in a 5% CO2 incubator. All experiments were performed with cells between 
passages 4 and 8.  
 
Immunofluorescence 
 
         The expression level of factor VIII was detected by immunofluorescence performed as reported (Shen et al., 
2010). For cell imaging, cells were cultured onto acid-washed, fibronectin-coated glass cover slips and allowed to adhere 
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overnight. The expression of factor VIII was detected by using the rabbit anti-rat factor VIII antibody (Zhongshan Co., 
Beijing,China) and the FITC conjugated human anti-rabbit IgG (Santa Cruz, CA, USA). The slides were observed and 
pictures were taken under a fluorescence microscope (Olympus, Tokyo, Japan). 
 
In vitro cell viability assay 
 
         The in vitro experiments with HUVECs included three groups: the normal control group without any treatment 
(NC group), the control serum group (S group), and the QDTM medicated serum group (Q group). For the S and Q groups, 
the HUVECs were incubated with 10% saline in medicated serum and 10% QDTM in medicated serum, respectively, and 
grown at 37 C in a humidified atmosphere with 5% CO2 and 2% oxygen for 24 h. Cell viability was determined by the 
MTT assay as described previously (Bittner et al., 2010; Perier et al., 2010). The extent of reduction of MTT to formazan 
within cells was quantified by the measurement of optical density at 490 nm with a micro-plate reader (Sigma-Aldrich，St. 
Louis, MO) (Wang et al., 2011a). 
 
Determination of apoptosis by flow cytometry 
 
         Apoptosis was analyzed by flow cytometry with Hoechst 33342/PI staining. The cultured HUVECs were washed 
with PBS twice, resuspended in PBS, and incubated with Hoechst 33342 at 37 C for 10 min. Next, suspensions were 
centrifuged again to obtain cell pellets. Cells were stained with 1 ml propidium iodide (PI) at 4 C for 15 min and then 
detected using an Epics Altra II flow cytometer (Beckman, Los Angles, CA, USA) (Wang et al., 2011b). 
 
Determination of effects of QDTM on rats following hypoxia treatment 
 
         A total of 30 SD rats were randomly assigned to one of three groups: the normal control (NC) (n = 6); hypoxia 
and saline (H + S) (n = 12); and hypoxia and QDTM (H + Q) groups (n = 12). For the NC group, rats were maintained at 
normal pressure and normal oxygen. For the other two groups, hypoxia was induced by placing the rats into a hypobaric 
hypoxia cabinet (Chakkarapani et al., 2010; Fan et al., 2010) with 6 h/day discontinuous hypoxia (360 mm Hg). For the H + 
S group, 1 ml/100 g saline was orally administered to each rat twice a day for 4 days before the hypoxia treatment. For the H 
+ Q group, 1 ml/100 g QDTM solution (32.4 g/ml) was orally administered to each rat twice a day for 4 days before hypoxia 
treatment. At 7 and 14 days after the hypoxia treatment, six rats from each groups were sacrificed; blood samples were taken 
from the femoral artery and the livers were harvested and fixed in formalin for 24 h. Sera were obtained and stored at –80 C 
for further use.  
 
Histology analysis 
 
         The formalin-fixed liver tissues were washed, dehydrated in a graded ethanol series, and embedded in paraffin. 
Sections (5 m) were cut transversely and stained with haematoxylin and eosin (HE) (Shen et al., 2010; Wang et al., 2011c) 
for light microscopic investigation. 
 
Transmission Electron microscopy 
 
         HUVECs then were washed, digested, resuspended, and centrifuged (1000 rpm) and then the pellet was harvested. 
For electron microscopy, the pellets and livers were fixed in 30 ml/L glutaraldehyde, and then postfixed with osmium 
tetraoxide, dehydrated in a graded ethanol series, and embedded in epoxy resin. Samples were sectioned (50 nm), stained 
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with uranyl acetate and lead citrate, and observed under a JEM-1200EX Electron Microscope TEM (Japan Electron Optics 
Ltd., Peabody, Japan) (Lamhonwah et al., 2010).  
 
Determination of serum VEGF-A levels by ELISA 
 
         Serum was inactivated at 56 oC for 30 min and filtered with a 0.22 μm filter membrane. The serum VEGF-A 
levels were determined using the ELISA method (Zheng et al., 2010) according to the manufacturer’s instruction (Sen Xiong 
Corp, Shanghai, China). 
 
Statistical Analysis  
 
         The experimental data were expressed as mean ± standard deviation (SD). Comparisons among groups were 
conducted with analysis of variance (ANOVA) or an unpaired t-test with SPSS software (Version 11.5, Chicago, IL, USA). P 
< 0.05 was considered significant. 
 
 
Results 
Morphological analysis of HUVECs  
 
         The morphological characteristics of the untreated HUVECs were observed under an inverted phase contrast 
microscope. As shown in Figure 1A, typical slab stone-looking monolayer cells were observed, which is characteristic of 
endothelial cells. Factor VIII expression was detected by immunofluorescence. As shown in Figure 1B, factor VIII was 
positively stained in cultured HUVECs.   
 
 
 
Figure 1: Cultured human umbilical vein endothelial cells (HUVECs). (A) HUVECs in confluence (×100); (B) Factor VIII 
was stained by anti-factor VIII antibody and then FITC conjugated human anti-rabbit IgG (green). Images were 
obtained by fluorescence microscopy. 
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Figure 2: Transmission electron microscopy evidence that QDTM protects human umbilical vein endothelial cells 
(HUVECs) from hypoxia-induced damage. QDTM medicated serum from SD rats (See Methods section for detailed 
information) was added to cell culture medium to determine the effect of QDTM on hypoxia-treated HUVECs. 
Representative images are shown. (A) NC (normal control) group (×200); (B) H + S (hypoxia + saline) group (×200); 
(C) H + Q (hypoxia + QDTM treatment) group (×200).   
 
Effects of QDTM on microarchitecture of HUVECs under hypoxia  
 
         To evaluate whether QDTM can protect HUVECs from hypoxia stress, we observed the microarchitecture of 
HUVECs after hypoxia treatment using an electronic microscope. As shown in Figure 2A, typical Weible-Palade bodies 
were observed in HUVECs in the NC group, indicating the integrity of the microarchitecture. As expected, cell necrosis, 
karyolysis, and broken cell membranes were observed in the HUVECs of the S group (Figure 2B). However, Weible-Palade 
bodies and some membrane-like structure were observed in the HUVECs in the Q group (Fig. 2C), indicating that QDTM 
protected the microarchitecture of HUVECs following hypoxia treatment.   
 
Effects of QDTM on cell viability and apoptosis of HUVECs under hypoxia  
 
         Next, we determined the effects of QDTM on cell viability and apoptosis of HUVECs. As shown in Figure 3A, 
the cell viability of HUVECs in the S group was significantly decreased by hypoxia treatment compared with that in the 
control group (n = 8, P < 0.05). However, treatment with QDTM significantly prevented the decrease of cell viability in 
HUVECs compared with the saline control (n = 8; P < 0.05). Moreover, as shown in Figure 3B, compared with the normal 
control, hypoxia induced obvious apoptosis in S group (n =3, P < 0.05), whereas treatment with QDTM significantly 
prevented apoptosis (n =3, P < 0.05).  
 
In vivo effects of QDTM on liver and endothelial cells following hypoxia treatment 
 
         We next investigated the in vivo effects of QDTM on the liver and endothelial cells in rats. As shown in Figure 
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4A, the morphology of the liver was normal in the NC group. Hypoxia treatment for 7 days induced cell swelling in 
endothelial cells of central hepatic veins in the H + S group (Figure 4B). Irregular arrangement, degeneration, and swelling 
were observed under the electronic microscope (Figures 4F and G). The changes in the microarchitecture of endothelial cells 
of rats treated with hypoxia for 14 days were markedly more severe (Figure 4C) than those in rats treated with hypoxia for 7 
days. However, pretreatment with QDTM for 4 days partly prevented these histological alterations in rats receiving hypoxia 
treatment for 7 (Figures 4D and H) and 14 days (Figures 4E and I). 
 
 
Figure 3: QDTM protects HUVECs from hypoxia-induced damage, as shown by cell viability analysis and apoptosis 
analysis. (A) Cell viability was determined by MTT assay. n = 8, *P < 0.05 vs. normal control; #P < 0.05 vs. hypoxia + 
saline group. (B) Apoptosis rate was determined by Hoechst 33342/PI staining with flow cytometry. n = 8, *P < 0.05 
vs. normal control; #P < 0.05 vs. hypoxia + saline group. 
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Figure 4:  QDTM protects liver and endothelial cells from hypoxia-induced damage in rats as detected by histological 
staining and electronic microscopy. QDTM solution (32.4 g/ml) or saline was orally administered (1 ml/100 g) for 4 
days before hypoxia treatment (7 and 14 days). Tissues were fixed and then stained with haematoxylin and eosin (HE) 
for light microscopy (A–E) or stained with uranyl acetate and lead citrate for electronic microscopy (F–I). (A) NC 
group; (B, F, and G) H + S group with 7 days hypoxia treatment; (C) H + S group with 14 days hypoxia treatment; (D, 
H) H + Q group with 7 days hypoxia treatment; (E, I) H + Q group with 14 days hypoxia treatment.  
 
 
Effects of QDTM on serum VEGF-A level 
 
         We measured the serum VEGF-A levels in rats to determine whether QDTM could affect the expression of 
VEGF-A after hypoxia. Hypoxia treatment for 7 or 14 days significantly enhanced the serum VEGF-A levels compared with 
normal control rats (n = 6, P < 0.01, Figure 5A). The pre-administration of QDTM for 4 days did not lower the serum 
VEGF-A level in rats on day 7, but it suppressed the upregulation of serum VEGF-A in rats on day 14 after hypoxia 
treatment (n = 6, P < 0.01, Figure 5B).  
 
 
Discussion 
 
         Although the underlying mechanisms for TCM’s effects on various biological systems are not fully understood, 
the merits of their use in the treatment of chronic diseases are gradually being recognized worldwide. QDTM has been used 
to treat various diseases or pathological conditions, such as angina, myocardial ischemia, coronary artery disease, and other 
cardiovascular diseases. Our previous studies indicated that QDTM can protect the left ventricle against acute myocardial 
ischemia in dogs (Ma et al., 2000) and decrease the serum lipid levels in type 2 diabetes patients (Zhang et al., 2001b). All of 
these findings prompted us to study whether QDTM can exert protective effects against endothelial dysfunction and play a 
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key role in preventing endothelial damages induced by ischemia.  
          
 
 
Figure 5: Serum VEGF-A levels were determined by ELISA. QDTM solution (32.4 g/ml) or saline was orally administered 
(1 ml/100 g) for 4 days before hypoxia treatment (7 and 14 days). (A) Serum VEGF-A levels at 7 days after hypoxia 
treatment. n = 6, *P < 0.05 vs. normal control; #P < 0.05 vs. hypoxia + saline group. (B) Serum VEGF-A levels at 14 
days after hypoxia treatment. n = 6, *P < 0.05 vs. normal control; #P < 0.05 vs. hypoxia + saline group. 
 
 
         The present study produced three major findings. First, QDTM protected endothelial cells from hypoxia-induced 
damage in vitro, as shown by electronic microscopy, cell viability analysis, and apoptosis analysis in vitro. Second, oral 
administration of QDTM successfully ameliorated hypoxia-induced injury of hepatic veins, as shown by light and electronic 
microscopy. Third, hypoxia treatment for 7 and 14 days upregulated serum VEGF-A levels. Pretreatment with QDTM did 
not reverse the changes on day 7 but attenuated the serum VEGF-A levels by day 14. These findings may help us better 
understand the mechanisms of action of QDTM in treating cardiovascular diseases. 
         Our studies of the effects of QDTM on endothelial functions indicated that QDTM can protect endothelial cells 
from hypoxia-induced damage both in vitro and in vivo. These effects may result from the components in this particular 
combination of TCMs. Notably, there are some reports of the cardiovascular effects of Astragalus (Zhang et al., 2005; Zhang 
et al., 2007), Angelica sinensis (Hou et al., 2004), and Carthamus tinctorius (Ji et al., 2009; Ji et al., 2008). In the present 
study, our results supported the postulated protective effects of QDTM under hypoxia.  
         Herein, we asked the following question: How does QDTM act as an endothelial protector? A possible answer is 
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that it acts via a VEGF-A-mediated mechanism. Among the seven members of the VEGF family, VEGF-A is the critical 
regulator of angiogenesis and vascular permeability. VEGF-A is a potent factor that can induce cell proliferation, shape 
change, and migration during angiogenesis (Tammela et al., 2005). Hypoxia can increase VEGF-A expression via 
upregulation of HIF1- (Ryu et al., 2008). In our study, QDTM modulated serum VEGF-A levels both positively and 
negatively, depending on the time after hypoxia treatment. Previous reports have indicated that VEGF-A can be a protector 
(Adya et al., 2008; Dai et al., 2007) or a damager (Ferrara et al., 2003; Kopfstein et al., 2007) depending on its concentration. 
After injury, a low level of VEGF-A mediates angiogenesis (Benest et al., 2008), whereas a high level of VEGF-A is harmful 
in some cases (Kaner et al., 2000; Niimi et al., 2000). We surmise that the increase of VEGF-A levels at 7 days after hypoxia 
was beneficial for angiogenesis and vascular repairing; however, when the VEGF-A level reached a level that was about 
three-fold higher than that of normal rats at 14 days after hypoxia treatment, this level of increase was harmful. Thus, QDTM 
was helpful for increasing VEGF-A levels at 7 days and for downregulating VEGF-A levels at 14 days after hypoxia 
treatment when the VEGF-A level was too high. However, future studies are needed to determine the molecular mechanisms 
for this bi-phase phenomenon.   
         In China, QDTM is always applied with other common cardiovascular drugs such as statins, ARBs and ACEI; 
however, it seems that there was no available data addressing the comparison between QDTM and other currently applied 
drugs in cardiovascular diseases yet. In this regard, future clinical multicentric perspective study is warranted for the 
comparison between QDTM and other cardiovascular drugs. 
         In conclusion, the present study demonstrated that QDTM protected endothelial cells from hypoxia-induced 
damage as measured by cell viability assay, apoptosis analysis, and electronic microscopy in vitro and in vivo. Our results 
provide new evidence for the therapeutic value of QDTM in the treatment of cardiovascular diseases. Our data suggest that 
alterations of VEGF-A levels may contribute to the protective effects of QDTM. 
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